Home > About Us > History   
 
  As a result of the 1984 KMA review of 280 such enterprises' records of growth stability and profitability, Hyundai Pharmaceutical was accorded superior ranking for its introduction of innovative management techniques and the attainment of rationalized operations.
  In 1997, our company is presented a commemorative plaque by Cho Hung Bank as one of Korean major bank and our main bank and we are won official commendation as an exemplary taxpayer by Vice-Prime Minister and Minister of the Ministry of Finance and Economy.
  At one and the same time this recognition indicates both the company's actual track record as well as the general direction in which it is bound to move in the future. And once again Hyundai Pharmaceutical pledges that solid management practices coupled with the enthusiastic commitment of its personnel will form the foundation for its continued advancement on the domestic and international scenes.



Date
Contents
2020
US FDA approved HD-6277 phase 2 IND for the treatment of type2 diabetes.
2019
Acquired ISO 37001 Certification
2019
Research contract for the "development of soft tissue-hardening compounds"
2019
American Diabetes Association (ADA) - Poster presentation of the result for the Phase 1 clinical trial of new anti-diabetes drug
2019
To achieve accident-free eight multiple(3,764 days)
2018
Compliance Program grade "AA" acquisition by Fair Trade Commission compliance program.
2018
5th Certificate of Consumer-Centered Management
2018
Sulfolase CR Tab. release
2017
Re-Certificate for excellence organization in Arts Council Korea
2017
'Sang-Jun, Lee', inaugurated as President
2017
'ArtMplus' Recertification for excellence organization in Arts Council Korea
2017
European Association for the study of Diabetes(EASD) - Poster presentation
2017
'The 50th Occupational health and safety's Day', Awarded for a man of merit Accident Prevention
2017
American Diabetes Association(ADA) - Poster presentation
2017
HD-6277(Candidiate Material of Diabets New Durg) has been approved the phase 1 clinical trial in Euroup.
2016
Recertification for Consumer Centered Management (CCM)
2016
Acquired the certificate of exellence laboratory for Safety management hosted Ministry of Science and ICT
2016
Selected as Continuity task for development of Diabets new drug
2016
'Aslan001' Designation of Orphan Drug in FDA
2016
Delivery of the relief medicine Worth KRW 1.3 billion for earthquake damage in Ecuadore
2015
'The 20th Consumer's day' Commendation of Fair Trade Commissioner
2015
'IP-R&D excellence organization' Prime the minister award of Ministry of Trade, Industry and Energy
2015
Prime the silver prize in the national president in National Quality Management Congress
2015
Contract the Technical introduction of gallbladder cancer medicine
2015
Hold Concert of Menopause Day
2015
Apply the Composition patent of Tranexamic acid externals at 10 countries abroad
2015
Development of candidiate Material of New Durg for Type 2 diabetes targeting GPR119 receptor
2015
Levotuss CR tab. Start up the Phase 3 Clinical trial
2015
Hyundai Pharmaceutical Co., LTD. Technical tranfer agreement with University-Industry Cooperation Foundation, Konkuk University
2015
Certificate for excellence organization in Arts Council Korea
2014
Commendation of Fair Trade Commissioner in CCM sector for the first in the pharmaceutical industry
2014
¡®HD-2356¡¯ has been selected as a project supported by the Ministry of Health & Welfare
2014
Hyundai Pharmaceutical Co., Ltd. signed license-out and supply agreement of Surfolase with Novotek, China
2013
'Young-Hak, Kim', inaugurated as President
2013
¡®HD-6277(GPR40 agonist)¡¯ has been selected as a project supported by the government
2013
¡®Choline alfoscerate SR¡¯ has been selected as one of projects supported by Ministry of Health and Welfare.
2013
Registed of patent for Levotuss (Levodropropizine) CR tablet
2012
Sulforase CR tablet was selected for R&D support project by the Ministry of Health & Welfare
2012
Recertification for Consumer Centered Management (CCM)
2012
Hyundai Pharmaceutical Co., LTD. signed the marketing and sales agreement of TachoSil®
2012
Signed technology transfer agreeemnt to Europe for Pramipexole sustained release tablet
2012
Selected as innovative pharmaceutical company by Ministry of Health & Welfare
2012
Designated as ATC (Advanced Technology Center) by Ministry of Knowledge Economy for development of new pharmaceutical products.
2012
Signed technology transfer agreement for new molecule of anti-obesity with Yonsei University
2011
Hit 15,000 of Noksaekjikimi (³ì»öÁöÅ´ÀÌ), Hyundai's suggestion system for innovation
2011
Signed co-promotion agreement of Ocuvite with BauschLomb
2011
Signed license-in agreement of Ruping eye drop (artificial tear) with Ophtecs corp, Japan
2011
Established a new R&D center in Yongin-si
2011
Made an agreement to donate for culture promotion with ¡®Art Council Korea¡¯
2011
Took out a patent for ingredient of hypertension
2010
Recertification for Consumer Complaints Management System (CCMS)
2010
Made an agreement about home sales for ¡®Natto Balance¡¯ with ¡®Nitto Pharmaceutical Industries of Japan¡¯
2010
Made an agreement about home sales for ¡®Nasalguard¡¯ with ¡®Nitto Pharmaceutical Industries of Japan¡¯
2010
Made an agreement about tie-in promotion with ¡®Merck of Germany¡¯
2010
Made the move to an office building located in Gangnam-gu
2010
Our CEO, ¡®Han-Koo Lee¡¯ was awarded the 47th prize of Dong-am¡¯s drugs
2010
Were chosen again as the best company of management for the risk of fire (from Korean Fire Protection Association)
2009
Our CEO, ¡®Han-Koo Lee¡¯ was awarded the Silver Industrial Medal by the government (from the 35th national competition of quality management)
2009
Over 10,000 about keeping safety
2009
Launched ¡®Tamirin TAB¡¯ which is a medicine for Alzheimer (for the first time in a domestic market)
2009
Signed the MOU regarding informing correct pharmaceutical information on the Internet with ¡®DAUM¡¯
2009
Got an approval from ¡®Korea Food and Drug Administration¡¯ regarding the clinical trial of HD-003, a new medicine
2009
Were chosen as the best company of management for the risk of fire (from Korean Fire Protection Association)
2009
Made an agreement about co-development for HFT-401, a new medicine for arthritis, with Forhumantech
2009
Established a new R&D center in Bio center in Gyeonggi-do
2008
Received a President Award in National Quality Management Competition and CCMS (Consumer Complaints Management System) certification. (1st time in Korean Pharmaceutical Industry)
2007
Changed Corporate Identity (CI)
2006
Awarded a grand prize for management value by Korean Government
2005
2005 Awarded for safe management by the National President (top honor given by Korean Government)
2002
Construction of New Factory (Wall-San Factory)
Research funding at University of Glasgow and University of Strathclyde
2001
Acquired ISO 14001 certificate
Invested to take stake to Korean Biotech Company (A&Pep, MedexBio)
2000
Acquired ISO 9001 certificate
Invested to take stake to Korean Biotech Company (Biobud)
1999
Acquired worldwide patent for NSC-peptide synthesis
1997
Elected Best Productivity Company Among All Listed Companies in Korea
1993
1993 Built a Plant at Hap-Cheon (Health Food Drink)
1989
Started Production of Health Food Drink
1985
Completed KGMP Plant at Cheon-Ahn (Pharmaceuticals)
1984
Awarded for Best Enterprise by Korea Management Association
1978
Listed at Korean Stock Market
1973
Changed Corporate Name to Hyundai Pharmaceutical Ind. Co., Ltd.
1965
Founded Hyundai Disinfection Chemical Ind. Co., Ltd
 
main_footer